FDA Accepts ANDA for Fluvoxamine Maleate by APPCO
The FDA has accepted the Abbreviated New Drug Application (ANDA) for Fluvoxamine Maleate submitted by APPCO.
Published: July 11, 2026
Updated: July 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Psychiatry / SSRI
Asset: APPCO
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
APPCO
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of APPCO's ANDA for Fluvoxamine Maleate signals increased competition in the SSRI market, which could impact pricing and market share for existing products. Portfolio teams must evaluate the implications for their SSRIs and adjust strategies accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for approval and any subsequent market entry by APPCO.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.